证券代码：002622 证券简称：皓宸医疗 公告编号：2025-003 皓宸医疗科技股份有限公司 第五届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届监事会第十四次会 议于 2025 年 4 月 14 日以电话、电子邮件的形式发出会议通知，会议于 2025 年 4 月 25 日上午 11:00 以现场结合通讯表决的方式召开。会议应参加表决监事 3 人，实际参加表决监事 3 人。会议由监事会主席刘月先生召集并主持，会议的内 容以及召集、召开的方式、程序均符合《公司法》和《公司章程》的规定。 与会监事经审议，通过如下议案： 一、审议通过《关于<2024 年度监事会工作报告〉的议案》 表决情况：同意 3 票，反对 0 票，弃权 0 票； 表决结果：通过。 本议案需提交公司 2024 年度股东大会审议。 《2024 年度监事会工作报告》全文详见公司指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）2025 年 4 月 26 日公告。 二、审议通过《关于<2024 年度财务决 ...

皓宸医疗科技股份有限公司（以下简称"公司"）聘请众华会计师事务所（特 殊普通合伙）为公司 2024 年度审计机构，众华会计师事务所（特殊普通合伙） 为公司 2024 年度财务报告出具了带强调事项段的无保留意见审计报告。根据中 国证监会《公开发行证券的公司信息披露编报规则第 14 号——非标准审计意见 及其涉及事项的处理》和《深圳证券交易所股票上市规则》等法律法规、规章制 定的要求，公司监事会认真审阅了董事会出具的专项说明，并发表如下审核意见： 皓宸医疗科技股份有限公司监事会 关于《董事会关于 2024 年度带强调事项段无保留意见审计报 告的专项说明》的意见 皓宸医疗科技股份有限公司监事会 二〇二五年四月二十五日 公司监事会认为：《董事会关于 2024 年度带强调事项段无保留意见审计报告 的专项说明》客观、真实，符合公司实际情况。监事会将充分发挥本职功能，积 极关注并督促董事会和管理层及时提示相关方解决相关问题，积极做好信息披露 工作，切实维护公司及全体股东，特别是中小股东的合法权益，保障公司持续、 稳定、健康发展。 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-002 皓宸医疗科技股份有限公司 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届董事会第十四次会 议于 2025 年 4 月 25 日上午 10:00 以现场结合通讯表决的方式召开。召开本次会 议的通知已于 2025 年 4 月 14 日以电话、电子邮件等方式通知了各位董事。本次 会议由董事长陆璐女士主持，会议应出席董事 7 名，实际出席董事 7 名。此次会 议的召集、召开与表决程序符合《中华人民共和国公司法》和《公司章程》及相 关法律、法规的规定，合法有效。 经与会董事认真审议并表决，通过了以下议案： 一、审议通过《关于<2024 年度董事会工作报告>的议案》 表决情况：同意 7 票，反对 0 票，弃权 0 票； 表决结果：通过。 本议案需提交公司 2024 年度股东大会审议。 《2024 年度董事会工作报告》具体内容详见公司指定信息披露网站巨潮资 讯网（www.cninfo.com.cn）2025 年 4 月 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-006 皓宸医疗科技股份有限公司 关于 2024 年度拟不进行利润分配的专项说明 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 第五届董事会第十四次会议及第五届监事会第十四次会议，审议通过了《关于< 公司 2024 年度利润分配预案>的议案》。根据《公司法》及《公司章程》等有关 规定，该事项需提交股东大会审议。现将具体情况公告如下： 一、公司 2024 年度利润分配预案 根据众华会计师事务所（特殊普通合伙）出具的公司 2024 年度审计报告， 截至 2024 年 12 月 31 日，公司合并财务报表未分配利润余额为-455,808,714.88 元，母公司财务报表未分配利润余额为-371,184,054.27 元。公司 2024 年度实 现归属于上市公司股东的净利润为-37,690,897.81 元，母公司实现净利润为- 40,345,955.75 元。 经公司第五届董事会第十四次会议审议通过，公司拟定 2024 ...

三、分红送配方案情况 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 29860.41万股，累计占流通股比： 35.54%，较上期变化： 570.00万股。 | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 广州汇垠日丰投资合伙企业(有限合伙) | 20000.00 | 23.81 | 不变 | | 陕西省国际信托股份有限公司-陕国投·鑫鑫向荣78号证券 | | | | | 投资集合资金信托计划 | 3226.32 | 3.84 | 不变 | | 青岛鑫汇合投资管理有限公司 | 1506.10 | 1.79 | 不变 | | 王存斌 | 1385.91 | 1.65 | 不变 | | 徐宝春 | 905.83 | 1.08 | -159.86 | | 中信证券股份有限公司 | 808.08 | 0.96 | 新进 | | 上海清淙投资管理有限公司-清淙睿智一号私募证券投资基 | | | | | 金 | 600.00 | 0.71 | 新进 | | 郏森茂 | 520.34 | 0.62 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan, representing a year-over-year growth of 15%[15]. - The company's operating revenue for 2024 was ¥861,568,412.49, representing a 13.86% increase compared to ¥756,709,758.78 in 2023[22]. - The net profit attributable to shareholders for 2024 was -¥37,690,897.81, a 60.06% improvement from -¥94,365,092.81 in 2023[22]. - The company reported a net profit margin of 12%, up from 10% in the previous quarter[9]. - The medical dental service sector contributed ¥773,486,896.92, accounting for 89.78% of total revenue, with a growth of 13.94% compared to the previous year[56]. - The electrical switch industry generated ¥86,032,001.18, making up 9.98% of total revenue, with a year-on-year increase of 13.55%[56]. - Revenue from the dental medical industry reached ¥773,486,896.92, an increase of 13.94% year-over-year, with a gross margin of 50.10%[58]. - Domestic sales amounted to ¥861,568,412.49, up 13.86% year-over-year, with a gross margin of 48.33%[58]. User Growth and Market Expansion - User data indicates a growth in active users, reaching 500,000, which is a 20% increase compared to the previous year[15]. - The company plans to expand its market presence by entering three new provinces in the upcoming year, targeting a 25% increase in market share[15]. - Market expansion efforts have led to a 25% increase in presence across three new regions[6]. Product Development and Innovation - New product development includes the launch of a cutting-edge dental imaging system, expected to enhance service efficiency by 30%[15]. - The company is focused on developing new products and expanding its market presence in the electrical industry, aligning with national manufacturing strategies[34]. - The company is committed to digital transformation and innovation in the dental medical industry, aiming to improve service quality and patient experience[33]. - The company has allocated 100 million yuan for research and development in innovative medical technologies over the next two years[15]. - The company has received 2 new invention patents and 3 utility model patents in 2024, further strengthening its intellectual property portfolio[45]. Financial Management and Governance - The board has decided not to distribute cash dividends for this fiscal year, focusing on reinvestment for growth[5]. - The company emphasizes its commitment to corporate governance and transparency, ensuring all financial reports are audited and accurate[4]. - The company has established a complete and independent financial accounting department, ensuring no shared bank accounts with related parties[119]. - The company has a governance structure that complies with the requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange[111]. Risk Management - The company is actively monitoring potential risks related to market fluctuations and regulatory changes, with a detailed risk management plan in place[4]. - The company emphasizes the importance of strict risk control and scientific investment decisions to ensure stable development in the future[107]. Employee and Management Structure - The total number of employees at the end of the reporting period was 1,714, with 1,752 employees receiving salaries during the period[148]. - The company has a diverse management team with backgrounds in finance, law, and clinical medicine[125][126]. - The company has implemented a strict compensation management system, linking employee salaries to company performance[150]. Social Responsibility and Community Engagement - The company actively engages in social responsibility initiatives, focusing on product safety, environmental protection, and employee rights[162]. - The company participates in community health initiatives, such as free medical consultations for underprivileged women during International Women's Day[163]. Legal and Compliance Matters - The company received a civil judgment on September 27, 2024, which dismissed all litigation requests from Beijing Shoutuo Ronghui Investment Co., Ltd.[106]. - The company is currently involved in a litigation case with Jin Haitang Asset Management Co., with a disputed amount of ¥362.30 million, which has been classified as a contingent liability[193]. - The company received an unqualified audit report for the 2024 financial statements, with an emphasis on the ongoing litigation regarding control disputes[184].

Financial Performance - The company's revenue for Q1 2025 was ¥142,937,780.75, a decrease of 12.58% compared to ¥163,503,563.10 in the same period last year[5] - The net loss attributable to shareholders was ¥12,214,580.55, representing a 167.13% increase in losses from ¥4,572,538.15 year-over-year[5] - Net profit for the period was a loss of ¥18,003,655.24, compared to a loss of ¥7,025,281.32 in the previous period, representing an increase in losses of approximately 156.5%[19] - Total operating revenue decreased to ¥142,937,780.75 from ¥163,503,563.10, a decline of approximately 12.5% year-over-year[17] - Total operating costs reduced to ¥167,162,234.16 from ¥179,781,974.53, a decrease of about 7.1% year-over-year[17] - Other comprehensive income after tax was a loss of ¥3,764,533.94, compared to a gain of ¥900,341.54 in the previous period[19] - Total comprehensive income for the period was a loss of ¥21,768,189.18, compared to a loss of ¥6,124,939.78 in the previous period[19] Cash Flow - The net cash flow from operating activities was negative at ¥17,184,700.35, a decline of 43.83% compared to the previous year's figure of ¥-11,948,253.48[5] - Cash flow from operating activities showed a net outflow of ¥17,184,700.35, worsening from a net outflow of ¥11,948,253.48 in the prior period[19] - Investment activities cash outflow totaled 278,026.75, resulting in a net cash flow from investment activities of -278,026.75[20] - Financing activities cash outflow amounted to 4,008,248.21, leading to a net cash flow from financing activities of -4,008,248.21[20] - The net increase in cash and cash equivalents was -21,470,870.05, with an ending balance of 125,099,938.62[20] - The beginning balance of cash and cash equivalents was 146,570,808.67[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,457,181,348.51, down 2.69% from ¥1,497,483,643.54 at the end of the previous year[5] - Current assets decreased from CNY 296,422,510.85 to CNY 271,723,944.04, a reduction of about 8.3%[13] - Non-current assets decreased from CNY 1,201,061,132.69 to CNY 1,185,457,404.47, indicating a decline of approximately 1.3%[14] - Total liabilities decreased from CNY 1,054,436,349.33 to CNY 1,035,902,243.48, a decrease of about 1.4%[14] - The company's cash and cash equivalents decreased from CNY 147,693,180.87 to CNY 126,548,983.48, a decline of approximately 14.3%[13] - Accounts receivable decreased from CNY 39,169,433.88 to CNY 32,094,965.57, reflecting a decrease of about 18.0%[13] - Inventory decreased slightly from CNY 50,753,348.55 to CNY 49,266,292.91, a reduction of approximately 2.9%[13] - The company's short-term borrowings remained relatively stable, decreasing slightly from CNY 191,588,304.03 to CNY 191,458,466.67[14] - The total equity attributable to shareholders of the parent company decreased to ¥382,056,059.67 from ¥398,035,174.16, a decline of approximately 4.0%[18] - The total liabilities and equity amounted to ¥1,457,181,348.51, down from ¥1,497,483,643.54, reflecting a decrease of about 2.7%[18] Research and Development - Research and development expenses increased by ¥2,600,000, marking a 163% rise compared to the same period last year[8] - Research and development expenses increased significantly to ¥4,192,860.44 from ¥1,594,263.46, marking a rise of about 162.5% year-over-year[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 54,029, with the largest shareholder holding 23.81% of the shares[10] Government Support - The company received government subsidies amounting to ¥328,966.43, which positively impacted other income[7] Other Information - The company has not audited its first-quarter report[21] - The financial report for the year 2025 will first apply new accounting standards[22]

皓宸医疗科技股份有限公司 2024 年度 内部控制审计报告 D 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://accm6.gov.cn） 进行变 内部控制审计报告 众会字(2025)第 02983 号 皓宸医疗科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了皓 宸医疗科技股份有限公司(以下简称"皓宸医疗")2024年12月31日的财务报告内部控制 的有效性。 我们认为,皓宸医疗于 2024年12月 31 日按照《企业内部控制基本规范》和相关规定 在所有重大方面保持了有效的财务报告内部控制。 ZHONGHUA 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》的规定,建立健全和有效 实施内部控制,并评价其有效性是皓宸医疗董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变 化可能导致内部控制变 ...

您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行整 " . . . . 皓宸医疗科技股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来情况 的专项说明 众会字(2025)第 02985 号 皓宸医疗科技股份有限公司全体股东: 我们接受委托,依据《中国注册会计师执业准则》审计了皓宸医疗科技股份有限公司(以下简称"皓 宸医疗")2024年度的财务报表,包括 2024年 12月 31 日的合并及公司资产负债表,2024年度的合并 及公司利润表、合并及公司现金流量表、合并所有者权益变动表及公司所有者权益变动表以及财务报 表附注,并于 2025年 4 月 25 日出具了众会字(2025)第 02981 号《审计报告》。 皓宸医疗科技股份有限公司 2024 年度非经营性资金占用及其他 关联资金往来情况的专项说明 根据中国证券监督管理委员会《上市公司监管指引第 8 号 -- 上市公司资金往来、对外担保的监 管要求》的要求以及参照深圳证券交易所《深圳证券交易所上市公司自律监管指南第1号 -- 业务办 理》规定的非经营性资金占用及其他关联资金往来情况汇总表 ...

皓宸医疗科技股份有限公司 2024 年度 营业收入扣除情况专项审核报告 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行额 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mo.f.gov.cn）"进行额2 0 ZHONO 专项审核报告 众会字(2025) 第 02984 号 皓宸医疗科技股份有限公司全体股东: 我们接受委托,审计了皓宸医疗科技股份有限公司(以下简称"皓宸医疗")2024年度 的财务报表,包括2024年12月31日的合并及公司资产负债表,2024年度的合并及公司利 润表、合并及公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注,并于 2025年4月25日出具了众会字(2025)第 02981 号审计报告。同时,我们审核了后附的皓 宸医疗 2024 年度营业收入扣除情况表。 一、管理层的责任 皓宸医疗管理层的责任是提供真实、合法、完整的相关资料,按照《深圳证券交易所上 市规则》以及《深圳证券交易所上市公司自律监管指南第1号 -- 业务办理》的要求编制营 业收入扣除情况表,并保证其内容真实、准确、完整 ...